193902-81-7

Basic information

• Product Name: 4-(4-Boc-piperazin-1-yl)-3-chloroaniline
• Synonyms: 4-(4-Boc-piperazin-1-yl)-3-chloroaniline;tert-butyl 4-(4-amino-2-chlorophenyl)piperazine-1-carboxylate
• CAS NO: 193902-81-7
• Molecular Formula: C₁₅H₂₂ClN₃O₂
• Molecular Weight: 311.81
• Mol File: 193902-81-7.mol

Chemical Properties

• Boiling Point: 467.3 °C at 760 mmHg
• Flash Point: 236.4 °C
• Appearance: /
• Density: 1.226 g/cm³
• Vapor Pressure: 6.57E-09mmHg at 25°C
• Refractive Index: 1.574
• PKA: 6.63±0.10(Predicted)
• CAS DataBase Reference: 4-(4-Boc-piperazin-1-yl)-3-chloroaniline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-Boc-piperazin-1-yl)-3-chloroaniline(193902-81-7)
• EPA Substance Registry System: 4-(4-Boc-piperazin-1-yl)-3-chloroaniline(193902-81-7)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• Hazardous Substances Data: 193902-81-7(Hazardous Substances Data)

Usage

Uses

Used in Organic Chemistry Research:
4-(4-Boc-piperazin-1-yl)-3-chloroaniline is used as a building block for the synthesis of diverse chemical compounds due to its unique structure and functional groups.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 4-(4-Boc-piperazin-1-yl)-3-chloroaniline serves as an intermediate for the preparation of pharmaceuticals and biologically active molecules, contributing to the development of new drugs and therapeutic agents.
Used in Pharmaceutical Industry:
4-(4-Boc-piperazin-1-yl)-3-chloroaniline is used as a key intermediate in the synthesis of various pharmaceuticals, playing a crucial role in the development of new medications and improving existing ones.
Used in Biologically Active Molecule Synthesis:
4-(4-Boc-piperazin-1-yl)-3-chloroaniline is utilized as a precursor in the synthesis of biologically active molecules, which have potential applications in various therapeutic areas, including but not limited to, oncology, neurology, and cardiology.

InChI:InChI=1/C15H22ClN3O2/c1-15(2,3)21-14(20)19-8-6-18(7-9-19)13-5-4-11(17)10-12(13)16/h4-5,10H,6-9,17H2,1-3H3

Upstream product

• 350-30-1 3-chloro-4-fluoronitrobenzene 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 29682-39-1 1-bromo-2-chloro-4-nitrobenzene 
• 193902-80-6 tert-butyl 4-(2-chloro-4-nitro-phenyl)piperazine-1-carboxylate 

Downstream Products

• 1185844-89-6 C₂₅H₃₂ClN₃O₃ 
• 850628-96-5 4-[2-chloro-4-(8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-ylamino)phenyl]-piperazine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER

The invention provides compounds of the formula (1): or a salt or tautomer thereof wherein A, R1, R2, R3, R4, R5 and R6 are as defined herein. The compounds are inhibitors of Wee1 and/or PLK1 kinase and are envisaged to be useful in the treatment of cancers.

BICYCLIC INHIBITORS OF ALK

The present invention relates to compounds of formula (1) or pharmaceutical acceptable salts, wherein R1, X, Y, Z, A, B, G1, and n are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as ALK and methods of treating diseases such as cancer.

BICYCLIC CARBOXAMIDE INHIBITORS OF KINASES

Compounds of formula (I) or pharmaceutical acceptable salts are provided, wherein X1~X5, R1~R3, A, B, Z and n are defined in the description. And compositions containing said compounds, and the uses for inhibitors of kinases such as ALK, and the uses for treating cancer thereof are provided.

The identification of a series of novel, soluble non-peptidic neuropeptide y Y2 receptor antagonists

The identification and subsequent optimisation of a selective non-peptidic NPY Y2 antagonist series is described. This led to the development of amine 2, a selective, soluble NPY Y2 receptor antagonist with enhanced CNS exposure.

The identification and optimisation of novel and selective diamide neuropeptide Y Y2 receptor antagonists

A novel small molecule NPY Y2 antagonist (3) identified from high throughput screening is described. A subsequent SAR study and optimisation programme based around this molecule is also described, leading to the identification of potent and soluble pyridyl analogue 36.

UREA DERIVATIVE

The present invention relates to a urea derivative or a pharmacologically acceptable salt thereof having an excellent DGAT inhibitory effect. A urea derivative having the formula: [wherein R 1 is a C 6 -C 10 aryl group which may be independently mono- to pentasubstituted by a group selected from Substituent Group a or others; R 2 is a C 6 -C 10 aryl group which may be independently mono- to pentasubstituted by a group selected from Substituent Group a or others; E is a group having the formula (II) or the formula (III) (wherein R 3 is a hydrogen atom or others; R 4 and R 5 , which are the same or different, are a hydrogen atom or others; X and U, which are the same or different, are a group represented by the formula CH or others; m and n, which are the same or different, are 1 or another number) or others; and A is a group represented by the formula -NH-C(=O)- or others], or a pharmacologically acceptable salt thereof.

IMIDAZOQUINOLINES AS LIPID KINASE INHIBITORS

The invention relates to novel organic compounds of formula (I) processes for the preparation thereof, the application thereof in a process for the treatment of the human or animal body, the use thereof - alone or in combination with one or more other pharmaceutically active compounds - for the treatment of an inflammatory or obstructive airway disease, such as asthma, disorders commonly occurring in connection with transplantation, or a proliferative disease, such as a tumor disease.

Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4

Inhibition of the cell cycle kinase, cyclin-dependent kinase-4 (Cdk4), is expected to provide an effective method for the treatment of proliferative diseases such as cancer. The pyrido[2,3-d]-pyrimidin-7-one template has been identified previously as a privileged structure for the inhibition of ATP-dependent kinases, and good potency against Cdks has been reported for representative examples. Obtaining selectivity for individual Cdk enzymes, particularly Cdk4, has been challenging. Here, we report that the introduction of a methyl substituent at the C-5 position of the pyrido[2,3-d]pvrimidin-7-one template is sufficient to confer excellent selectivity for Cdk4 vs other Cdks and representative tyrosine kinases. Further optimization led to the identification of highly potent and selective inhibitors of Cdk4 that exhibit potent antiproliferative activity against human tumor cells in vitro. The most selective Cdk4 inhibitors were evaluated for antitumor activity against MDA-MB-435 human breast carcinoma xenografts in mice.

Fibrinogen receptor antagonists

This invention relates to compounds of the formula: which are effective for inhibiting platelet aggregation, pharmaceutical compositions for effecting such activity, and a method for inhibiting platelet aggregation.